Current Data and Strategy in Glioblastoma Multiforme
Author Information
Author(s): Iacob G, Dinca EB
Primary Institution: Carol Davila University of Medicine and Pharmacy
Conclusion
The prognosis of glioblastoma multiforme (GBM) remains poor, with median survival only extending to about 14 months despite treatment advancements.
Supporting Evidence
- GBM accounts for 12-15% of all brain tumors and has a median survival of just over 1 year.
- Patients who underwent resection had a median survival of 57 weeks compared to 38 weeks for those who were biopsied.
- The prognosis of GBM is still dismal, with a median survival of only 14 months with treatment.
Takeaway
Glioblastoma is a very aggressive brain cancer that is hard to treat, and even with the best care, most people only live about a year after being diagnosed.
Methodology
The study analyzed data from 118 patients treated for GBM, focusing on treatment outcomes and survival rates based on surgical intervention.
Potential Biases
Selection bias due to the nature of treatment options offered based on patient condition.
Limitations
The study may have selection bias as patients with more severe conditions were more likely to receive less invasive procedures like biopsy.
Participant Demographics
Patients treated in the Neurosurgery Clinic of the University Hospital, Bucharest, from 2003 to 2008.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website